Trial Profile
BCT 1703 (DIAmOND): An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms DIAmOND
- 22 Oct 2021 Planned number of patients changed from 50 to 75.
- 22 Oct 2021 Planned End Date changed from 31 May 2023 to 30 Nov 2024.
- 09 Apr 2021 Planned End Date changed from 1 Nov 2022 to 31 May 2023.